Celltrion, Inc.

Equities

A068270

KR7068270008

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 13/02/2026			5-day change	1st Jan Change
238,000.00 ^KRW	-0.21%		+3.48%	+31.49%

02-05	CVS Health to drop Amgen and Lilly's bone disease treatments from some drug lists (February 5)	RE
01-30	Celltrion Launches Autoimmune Drug Aptozma in Europe	MT

Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on September 17, 2025.

Published on 10/17/2025 at 12:52 pm BST

S&P Capital IQ

CELLTRION, INC.

-0.21%

From September 17, 2025 to October 15, 2025, the company has repurchased 572,932 shares, representing 0.26% for KRW 100,000.03 million. With this, the company has completed the repurchase of 572,932 shares, representing 0.26% for KRW 100,000.03 million under the buyback announced on September 17, 2025.

Latest news about Celltrion, Inc.

02-05	CVS Health to drop Amgen and Lilly's bone disease treatments from some drug lists (February 5)	RE
01-30	Celltrion Launches Autoimmune Drug Aptozma in Europe	MT
01-14	Celltrion Presents Innovative Drug Pipeline and U.S. Manufacturing and R&D Expansion Strategy At the 44Th Annual J.P. Morgan Healthcare Conference	CI
01-06	Abpro, Celltrion Say Solid Cancer Tumor Therapy Investigational New Drug Application Receives US FDA Clearance	MT
01-06	Abpro Holdings, Inc. and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72	CI
01-02	Health Care Up on Anti-Obesity Drug Sales Outlook - Health Care Roundup	DJ
01-02	Celltrion, Inc. acquired Biopharmaceutical Manufacturing Facility in the United States from Eli Lilly and Company (NYSE : LLY).	CI
01-02	Celltrion Shares Rally on U.S. Contract, Earnings Outlook	DJ
01-01	Celltrion Inc U.S. unit Celltrion USA signs production contract with Eli Lilly worth 473 million USD	RE
12-21	Samsung Biologics to buy US drug production facility from GSK for $280 million	RE
12-18	Celltrion, Inc. Receives Positive CHMP Opinion for SteQeyma (Uustekinumab Biosimilar) Autoinjector	CI
12-15	Abpro Holdings, Inc. and Celltrion, Inc. Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T Cell Engager ABP-102/CT-P72 for HER2-Positive Cancers	CI
12-11	Celltrion USA, Inc. announced that it expects to receive $532.1 million in funding from Celltrion, Inc.	CI
12-10	Celltrion, Inc. announces Annual dividend	CI
12-03	Celltrion Announces U.S. FDA Approval of 300mg strength of OMLYCLO®?	CI

Chart Celltrion, Inc.

Duration

Period

A068270: Dynamic Chart

Company Profile

Celltrion Inc is a Korea-based company mainly engaged in the production and sale of bio pharmaceuticals. The Company operates its business through two segments. The Bio Pharmaceutical segment produces and sells protein therapeutics such as anticancer drugs. In addition, this Segment develops monoclonal antibodies(mABs) that are used to treat chronic autoimmune diseases such as arthritis and severe diseases such as breast and colon cancer. The Chemical Pharmaceutical segment is mainly engaged in the manufacture and sale of chemical drugs. In addition, the Segment sells bio drugs, and provides services such as data analysis. The Company's main products include liver and bowel medicines and other generics. The main products sold by the Company include autoimmune disease treatment agents, anti-malignant tumor drugs and other products. The Company sells its products in domestic and overseas markets such as Europe and the United States.

Employees

2,680

Sector

Biotechnology & Medical Research

Calendar

03-24 - Annual General Meeting

More about the company